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Early detection of colonic polyps can prevent up to
90% of colorectal cancer deaths. Conventional colo-
noscopy readily detects the majority of premalignant
lesions, which exhibit raised morphology. However,
lesions that are flat and depressed are often unde-
tected using this method. Therefore, there is a need
for molecular-based contrast agents to improve
detection rates over conventional colonoscopy. We
evaluated a quenched fluorescent activity-based
probe (qABP; BMV109) that targets multiple cysteine
cathepsins that are overexpressed in intestinal
dysplasia in a genetic model of spontaneous intesti-
nal polyp formation and in a chemically induced
model of colorectal carcinoma. We found that the
qABP selectively targets cysteine cathepsins, result-
ing in high sensitivity and specificity for intestinal tu-
mors in mice and humans. Additionally, the qABP
can be administered by either intravenous injection
or by local delivery to the colon, making it a highly
valuable tool for improved detection of colorectal le-
sions using fluorescence-guided colonoscopy.
INTRODUCTION
Colorectal cancer is the second leading cause of cancer-related
mortality in the United States (Jemal et al., 2008). Colonoscopy
and sigmoidoscopy have been shown to reduce the incidence
of colorectal cancer-related deaths (Blumenstein et al., 2013).
During the past decade, awareness of screening options has
increased dramatically, helping improve early detection (Amersi
et al., 2005). Nevertheless, more than 20% of grossly visible
colorectal polyps remain undetectable by standard white-light
colonoscopy (Cheng et al., 2002). These undetectable lesions
include small and flat or depressed polyps with malignant po-
tential. Thus, there is an unmet medical need for new tools to148 Chemistry & Biology 22, 148–158, January 22, 2015 ª2015 Elsevimprove detection of colorectal polyps. Improvements in image
contrast for visualizing premalignant lesions will potentially
improve detection rates and consequently improve clinical out-
comes. Additionally, such tools may be useful for the evaluation
of responses to therapeutic interventions.
Proteases support tumorigenesis by facilitating cell division
and motility, mediating local invasion, and promoting angio-
genesis and metastasis (Lo´pez-Otı´n and Matrisian, 2007; Lo´-
pez-Otı´n and Overall, 2002). Cysteine cathepsins are a family
of lysosomal proteases that play important roles in various as-
pects of tumorigenesis (Gounaris et al., 2008) (Mohamed and
Sloane, 2006). In human cancers, particularly in colorectal tu-
mors, cathepsins B, C, D, H, L, S, and X have been shown to
be upregulated both in tumor cells and in associated stromal
cells, including in immune cells (i.e., macrophages, lymphocytes,
and neutrophils), endothelial cells, and fibroblasts (Hersze`nyi
et al., 1999; Mohamed and Sloane, 2006; Troy et al., 2004).
These observations have prompted efforts to target cathepsins
with molecular imaging agents as a strategy for detecting colo-
rectal malignancies. Over the past decade, numerous biosen-
sors have been developed for the purpose of imaging protease
activity in native environments (Bogdanov and Mazzanti, 2013;
Sanman and Bogyo, 2014). These include fluorescent (Boo-
nacker and Van Noorden, 2001) and bioluminescence protein
substrates (O’Brien et al., 2005; Shinde et al., 2006), macromo-
lecular and peptide substrate-based probes (Hu et al., 2014;
Mahmood et al., 1999; Olson et al., 2012; Saravanakumar
et al., 2012), and FRET protein reporters (Cummings et al.,
2002). Although many of these methods have shown promise
for contrast imaging, most have exhibited relatively poor selec-
tivity and specificity. Furthermore, several of these methods
require either the use of bulky cell-impermeable molecules with
slow turn-on rates or genetic manipulation of cells or organisms
to introduce reporters (Baruch et al., 2004). Substrate-based
probes also do not allow direct identification of the protease
target that activated the signal, thus making it difficult to assign
function to specific targets. An alternative method for visualizing
protease activity uses small-molecule probes that covalently
attach to an enzyme target through a chemical reaction that is
specific for the target protease (Terai and Nagano, 2008). Theseier Ltd All rights reserved
Figure 1. Structure and Mechanism of Ac-
tion of the qABP
(A) Structure of BMV109 highlighting the reactive
PMK electrophile that forms a covalent bond with
the active site cysteine (red) as well as the fluo-
rophore (green) and quencher (gray).
(B) Diagram of the mechanism of unquenching of
the probe upon binding to an active cysteine
protease target.
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Colon Cancer Imaging with Cathepsin Probesprobes, called activity-based probes (ABPs) (Fonovic and Bo-
gyo, 2007; Sanman and Bogyo, 2014), are designed to be highly
selective for the catalytically active form of a protease or prote-
ase family (Cravatt et al., 2008). Typical ABPs consist of three
main elements: (1) a reactive functional group that covalently re-
acts with the active site of the enzyme; (2) a linker region that
confers enzyme specificity, directs binding to the target, and
prevents steric congestion; and (3) a tag used for direct visuali-
zation of the probe-labeled proteins (Deu et al., 2012). An addi-
tional element that improves the sensitivity and specificity of
ABPs is a quencher that prevents fluorescent emission of un-
bound probe. Once the probe covalently binds to the target
enzyme, the quencher is removed and the probe emits the
desired fluorescent signal (Blum et al., 2005) (Figure 1B). The
benefit of the ABPs is that they are relatively small molecules
that can directly diffuse into tissues resulting in rapid turn on
rates in vivo (Edgington et al., 2011). This enables applications
in which probes are topically applied and imaging can be per-
formed within a time frame of minutes rather than hours (Cutter
et al., 2012).
In this study, we evaluated a recently reported, biocompatible,
optically quenched ABP (qABP), BMV109, that becomes fluores-
cent upon covalently binding to active cysteine cathepsins (Ver-Chemistry & Biology 22, 148–158, January 22, 2015does et al., 2013) for the detection of
intestinal cancer. This qABP selectively
labels a broad spectrum of cathepsins
in the intestines, primarily in the tumor
microenvironment. In multiple mouse
models, the probe exhibited strong label-
ing of polyps following not only intrave-
nous injection but also by local appli-
cation using intrarectal administration.
Furthermore, because the probe cova-
lently labels target proteases, we were
able to biochemically confirm selective
labeling of cysteine cathepsins. Direct
histological analysis of the whole intes-
tine enabled us to measure the selectivity
and specificity of the probe for polyps.
Using this method, we confirmed rapid
detection of lesions with high selectivity
and specificity ratios following either
intravenous or intrarectal administration.
We used the probe to topically label hu-
man tissue sections, demonstrating the
ability of the probe to detect human
polyps. These unique features make our
qABP a strong candidate for clinicaltranslation as a tool for use in fluorescence-guided colonoscopy
to enhance detection and surgical treatment of colon cancer.
RESULTS
The qABP Preferentially Labels Polyps of APCmin/+ Mice
We previously reported the synthesis and evaluation of a qABP
that was designed to selectively target a broad spectrum of
cysteine cathepsins (Verdoes et al., 2013). The probe is
composed of a phenoxymethyl ketone (PMK) electrophile, a
linker, a Cy5 fluorophore, and a sulfo-QSY21 quencher (Figures
1A and 1B). As an initial system to evaluate the ability of the
probe to label intestinal polyps, we used the well-established
APCmin/+ (multiple intestinal neoplasia) mouse model (Moser
et al., 1990). Thesemice carry amutation resulting in a premature
truncation of one allele of the APC tumor suppressor, analogous
to the human disease familial adenomatous polyposis. In both
the mouse model and human disease, spontaneous loss of the
other allele results in the development of multiple adenomas in
the intestine. In addition, this model has been used to evaluate
other classes of protease beacons (Clapper et al., 2011; Gouna-
ris et al., 2008). The qABP was injected intravenously into both
APCmin/+ and wild-type (WT) mice. A group of the APCmin/+ª2015 Elsevier Ltd All rights reserved 149
Figure 2. The qABP Preferentially Labels
Polyps in APCmin/+ Mice
(A) Ex vivo bright-field (left) and fluorescence op-
tical images (right) of the intestine tissue of WT
(top) and APCmin/+ (center and bottom) mice 1 hr
after intravenous administration of the probe. The
scale bar represents 5 mm.
(B) Correlation of signal intensity per millimeter per
millisecond (exposure time) with polyp diameters
(millimeters). Calculated correlation coefficient:
R2 = 0.823.
(C) Analysis of cathepsin labeling in samples from
surrounding normal tissues (left) compared with
polyp tissue (right) from three individual mice.
Samples were analyzed by SDS-PAGE followed
by flatbed laser scanning of the gel to visualize
probe-labeled proteins.
(D) Quantification of the intensity of labeled pro-
teins in (C). The p values are two sided (ANOVA).
Error bars represent the mean ± SD. *p < 0.05,
**p < 0.03, ***p < 0.01.
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Colon Cancer Imaging with Cathepsin Probesmice was treated with vehicle as a control. Mice were euthanized
1 hr later, and intestines were removed, flushed, and prepared
for ex vivo fluorescence imaging. Multiple variable-sized intesti-
nal polyps were observed in the tissues from APCmin/+ mice, with
strong fluorescent labeling of tumors in mice treated with
the qABP (Figure 2A). We also assessed whether cathepsin ac-
tivity levels correlated with polyp size by comparing fluorescent
signal intensity with polyp diameter. This analysis confirmed a
strong correlation between fluorescence signal and polyp size
(Figure 2B).
To identify the specific targets of the qABP, we performed
SDS-PAGE analysis of homogenized samples of polyps and
matched surrounding intestine dissected from APCmin/+ mice
(Figure 2C). The intensity of total cysteine cathepsin labeling
was 7-fold higher in polyps compared with uninvolved surround-
ing tissue (p = 0.00065; Figure 2D), similar to the ratio of polyp
signal to background observed in the fluorescence optical im-
ages. The labeling profile also confirmed that the probe is pan-150 Chemistry & Biology 22, 148–158, January 22, 2015 ª2015 Elsevier Ltd All rights reservereactive toward cysteine cathepsins and
that cathepsins X, B, S, and L are all upre-
gulated in the polyp tissues.
To confirm specificity of probe labeling,
APCmin/+ mice were treated with a broad-
spectrum inhibitor of the cysteine cathep-
sins for 5 days to reduce activity before
treatment with the qABP. This inhibitor,
K11777, is a dipeptide vinyl sulfone that
has been previously reported to block
cathepsin activity in vivo (Blum et al.,
2007). Fluorescence images from mice
treated with K11777 showed a substan-
tial drop in probe fluorescence in polyps
compared with the vehicle-treated sam-
ples (Figure 3A). This drop in signal within
the polyps correlated with a drop in the
total amount of labeled cathepsins, as as-
sessed by SDS-PAGE analysis and quan-
tification of labeling of resected colontissue (p = 0.0126; Figures 3B and 3C), thus confirming that
the qABP labels polyps by selective modification of active
cathepsins.
The qABP Labels Colitis-Associated Colonic Neoplasms
following Either Systemic or Local Administration
Chronic inflammatory bowel disease (IBD), particularly ulcerative
colitis, strongly predisposes individuals to develop colorectal
cancer. Therefore, we tested the ability of the probe to image
neoplasms in a mouse model of colitis-associated colorectal
cancer induced by azoxymethane (AOM) and dextran sodium
sulfate (DSS). We chose this model because it allows assess-
ment of the probe in a different model with clinical relevance to
colorectal cancer and because others have recently used a
similar colitis model to demonstrate the value of a substrate-
based cathepsin probe for detecting dysplasia that is induced
by colitis (Gounaris et al., 2013). Mice with colitis induced by
AOM/DSS were treated with the probe by either intravenousd
Figure 3. Probe Signal Intensity Correlates
with the Activity of the Cysteine Cathepsins
In Vivo
(A) Ex vivo fluorescence optical images overlaid on
bright-field images of intestines from APCmin/+
mice pretreated with either vehicle (top) no inhib-
itor (middle) or the K11777 inhibitor (bottom) 1 hr
after intravenous administration of the probe. The
scale bar represents 5 mm.
(B) Analysis of cathepsin labeling by the probe in
polyps from the APCmin/+ mice administered with
vehicle (left), the probe and no inhibitor (middle), or
the probe and K11777 (right). Samples were
analyzed by SDS-PAGE followed by flatbed laser
scanning of the gel to visualize probe labeled
proteins.
(C) Quantification of the intensity of labeled polyps
from (A, left) and labeled cathepsins in (B, right).
The p values are two sided (ANOVA). Error bars
represent the mean ± SD. *p < 0.05, **p < 0.03,
***p < 0.01.
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Colon Cancer Imaging with Cathepsin Probesinjection as performed for the APCmin/+mice or by direct intrarec-
tal administration into the colon. We reasoned that because the
probe is relatively low molecular weight and can diffuse into tis-
sues, local administration may be effective and a clinically valu-
able strategy. Control groups included AOM/DSS mice adminis-
tered intravenously or intrarectally with vehicle and noninduced
mice treated with the probe intravenously or intrarectally. In co-
lons dissected from AOM/DSS mice, we observed mainly
macroscopic polyps in the distal colon that were highly labeled
with the qABP upon either intravenous or intrarectal administra-
tion (Figure 4A). Autofluorescence was not detected in AOM/
DSS mice treated with the vehicle and nonspecific labeling in
noninduced mice treated with the probe was minimal. Further-
more, similar to our results in the APCmin/+ mice, we observed
a strong correlation between fluorescence signal and polyp
size for both the intravenous and intrarectal administration,
demonstrating their equivalent detection capabilities (Figure 4B).
To verify the targets of the probe and exclude the possibility
that signals observed in the fluorescence images resulted from
nonspecific interactionswith other protein targets, we performedChemistry & Biology 22, 148–158, January 22, 2015SDS-PAGE analysis on labeled tissues
(Figure 4C). Samples of surrounding tis-
sue and colonic polyps from AOM/DSS
mice treated with the probe (intrave-
nously or intrarectally) and samples from
AOM/DSS mice treated intrarectally with
vehicle were collected, homogenized
and analyzed. In tissues from mice that
were administered the probe intrarec-
tally, polyps showed strong labeling of
cathepsins X, B, S, and L, whereas no la-
beling of cathepsins was observed in
healthy mice. No labeling of cathepsins
was observed in mice administered
vehicle control intrarectally. In mice
administered the probe intravenously,
polyps showed strong labeling of cathep-
sins X and B and attenuated labeling ofcathepsin S and L, whereas some labeling of only cathepsins
X, B, L, and Swas observed in the surrounding tissue (Figure 4C).
Signal in surrounding tissue ofmice treated intravenouslymay be
the result of labeling of populations of immune cells in the circu-
lation or endothelial cells that are less directly targeted when the
probe is applied locally. When multiple samples from polyp and
normal surrounding tissues were analyzed (Figure S1 available
online) and quantified (Figure 4D), the total levels of cysteine
cathepsin labeling were 9-fold and 2.6-fold higher in polyps
compared with the surrounding tissue in mice treated with the
probe intrarectally (p = 0.0245) or intravenously (p = 0.0362),
respectively. These findings demonstrate that probe adminis-
tered either locally or systemically results in high selectivity for
cysteine cathepsins in colonic polyps.
Probe Labeling Is Associated with Regions of
Cytological and Architectural Abnormalities of the
Intestinal Epithelium
Increased proliferation is believed to be an early event of the ad-
enoma-carcinoma sequence (Jiang et al., 2013). Additionally,ª2015 Elsevier Ltd All rights reserved 151
Figure 4. The Probe Selectively Labels Cysteine Cathepsins Upregulated in Intestinal Adenomas and Adenocarcinomas
(A) Ex vivo bright-field (left) and fluorescence optical images (right) of the colon of untreated controls (top) and AOM/DSS (bottom) mice 1 hr after intravenous or
intrarectal administration of the probe. The scale bar represents 5 mm.
(B) Correlation of signal intensity per millimeter per millisecond (exposure time) with polyp diameters (millimeters) for multiple polyp samples from mice treated
intravenously (open triangles) or intrarectally (filled triangles). Calculated correlation coefficients: intrarectal R2 = 0.810, intravenous R2 = 0.843.
(C) Analysis of cathepsin labeling by the probe in surrounding normal tissue and polyps from the intrarectal vehicle (left), intrarectal probe (middle), and intra-
venous probe (right). Samples were analyzed by SDS-PAGE followed by flatbed laser scanning of the gel to visualize probe labeled proteins.
(D) Quantification of intensity of labeled cathepsins frommultiple samples (see Figure S1) from each treatment group (n = 3). The p values are two-sided (ANOVA).
Error bars represent the mean ± SD. *p < 0.05, **p < 0.03, ***p < 0.01.
See also Figure S1.
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Colon Cancer Imaging with Cathepsin Probesthe rate and distribution of proliferating epithelial and mucosal
cells has been used as a biomarker of neoplasia progress (Lipkin,
1988). We therefore examined if probe labeling correlates with
abnormal patterns of the intestinal epithelium such as cell
dysplasia (i.e., atypia, elongation, hyperchromatic nuclei, and
stratified nuclei). Because the probe permanently labels target
proteases, it was possible to perform direct histology and fluo-
rescence imaging of tissues sections to determine the extent
of probe accumulation in cancer lesions. We also evaluated
the distribution of CD68, a cellular marker for macrophages, in
samples from APCmin/+ and WT mice intestines by histology.
To collect and analyze data from the entire small intestine, we
used awide-field tile scan technique to generate amosaic image
of hematoxylin and eosin (H&E) and immunofluorescence stain-
ing (Figure S2). The intestinal mucosa from APCmin/+ mice
showed areas of increased proliferation at intestinal crypts. In
addition, intestinal microadenomas and adenomatous polyps
in APCmin/+ samples showed consistently increased CD68 stain-
ing compared with normal mucosa. Importantly, the probe did
not accumulate in the intestine of WT control mice, verifying
the specificity for polyps. Most regions of increased epithelial
proliferation, including adenomas, exhibited increased accumu-
lation of the probe in APCmin/+ mice. Using the ex vivo bright-field
and fluorescence images (Figures 2 and S3), we were able to
calculate the sensitivity and specificity of the probe for detecting
adenomas as 87.5%and 76.9%, respectively (Table S1). In addi-
tion, the positive and negative predictive valueswere determined
to be 90.3% and 71.4%, respectively (Table S1). We were also
able to calculate the sensitivity and specificity of the probe in
the AOM/DSS model using the ex vivo bright-field and fluores-
cence images (Figures 4 and S4). The sensitivity and specificity
for detecting colonic adenomas in mice intravenously treated
with the probe were 88.9% and 71.5%, respectively. The posi-
tive and the negative predictive values were 89.5% and
81.2%, respectively (Table S2). The sensitivity and specificity
in detecting colonic adenomas in mice treated with the probe
locally by intrarectal administration were 93.6% and 80.0%,
respectively (Table S2). The positive and negative predictive
values were 94.9% and 81.2%, respectively (Table S2). These
results demonstrate that the probe can be used by intravenous
or intrarectal administration to selectively label colitis-associated
colonic polyps.
Cathepsins Labeled by the Probe Colocalize with
Tumor-Associated Immune Cells in Both Models of
Colon Cancer
Numerous cell types in the tumor microenvironment express ca-
thepsins. To determine whether specific immune cells are the
major targets of the qABP in mouse tissues, we performed
immunofluorescence staining with the cell marker CD45 on in-
testine sections from both the APCmin/+ and AOM/DSS mice
treated with the qABP (Figure 5). These images show that
although signal is present in normal tissue, the probe accumu-
lates primarily in polyps. We observed that the probe localized
mainly to the lysosomal compartments of mononuclear cells in
the lamina propria. Because cysteine cathepsins aremainly lyso-
somal, the staining pattern matched expected observations.
Furthermore, the probe was found to accumulate mainly in tu-
mor-associated immune cells, as indicated by the labeling withChemistry & Biology 22, 148CD45 membrane protein staining. Importantly, these results
were similar in both models, confirming that the probe is able
to highlight general regions of inflammation in and around devel-
oping lesions in the intestine.
The qABP Labels Tumor-Associated Immune Cells in
Human Polyps
To assess whether the probe labeling of early cancer lesions in
mice was relevant to human disease, we tested the probe on hu-
man clinical samples. In order to do this, we obtained fresh
frozen tissue sections of matched human polyps and healthy
surrounding tissue. Because the probe could be applied topi-
cally, we directly labeled tissues sections following brief fixation
in acetone. We found that the probe very rapidly and selectively
labeled cells in tumors.We analyzed a total of fivematched polyp
and normal tissues by staining with the probe and generated tile
scan images, as we had performed for the mouse tissues (Fig-
ure 6). Although the signal intensity and frequency of cells with
probe staining varied between samples, there were consistently
increased levels of probe fluorescence in tumor tissue compared
with the matched healthy surrounding tissues. At a cellular level,
the probe was found to show rather diffuse labeling of mononu-
clear cells, with many of them exhibiting CD45 membrane stain-
ing. Similar to results in mouse tissues, these data confirm that
the probe is specific for inflammatory cells that are found in
cancerous lesions and suggest a great potential for translation
to clinical studies.
DISCUSSION
Removal of adenomatous colonic polyps during colonoscopy
significantly minimizes the risk for future malignancy and can-
cer-related death (Zauber et al., 2012). Conventional colonos-
copy is limited to the detection of pedunculated and visible
mucosal lesions, whereas flat or depressed polyps often escape
detection and have the potential to transform to malignant carci-
noma in asymptomatic patients (Buie and MacLean, 2008). In
addition, patients with chronic IBD are at increased risk for
developing malignancy due to undetected dysplastic lesions
(Mayer et al., 1999). Unfortunately, at present there is no clinically
approved molecular-based tool to improve detection of colo-
rectal adenomas and adenocarcinomas during optical colonos-
copy procedures. In this study, we have validated a method for
the detection of intestinal and colorectal adenomas using a
Cy5-labeled qABP with broad-spectrum reactivity for the
cysteine cathepsins. These results demonstrate that cysteine
cathepsin activity is a reliable biomarker of intestinal neoplasia
and demonstrate that our probe can be used to detect intestinal
polyps with high sensitivity and specificity when administered
either intravenously or intrarectally. The fluorescent signal gener-
ated by the bound probe correlates with polyp size and allows
the detection of adenomas from matched surrounding nonneo-
plastic mucosa. These results demonstrate that the qABP is a
promising tool for improving detection of colorectal adenomas
using colonoscopy.
To enhance the detection of colorectal adenomas, several op-
tical techniques have been developed, including chromoendo-
scopy, autofluorescence imaging, and narrow-band imaging
(Hurlstone and Sanders, 2006). Although they are valuable–158, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 153
Figure 5. Cathepsins Labeled by the Probe Colocalize with Macrophages in Intestinal Dysplasia and Colitis-Related Colonic Neoplasms
(A and B) Sections of confocal macroscopic mosaic images of intestine dissected from APCmin/+ (A) and AOM/DSS (B) mice. H&E (top left; the scale bar rep-
resents 250 mm) are shown alongwith DAPI (blue), probe (red), and anti-CD45 (green). Images are shown are mosaic images from tile scanning (top), 203 (bottom
left; the scale bar represents 100 mm) and 633magnification of the region indicated with a white box (lower right images; the scale bar represents 20 mm). Polyps
are indicated with white dashed lines. See also Figure S2.
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are subjected to image interpretation by the operator and cannot
be applied to determine polyp histology. Moreover, there have
been technical issues with false positives in patients with IBD
and misinterpretation of mucosal folds forming shadows in
healthy subjects (Taylor et al., 2007). Targetedmolecular labeling
has the potential to overcome these challenges by probing for
specific biomarkers that distinguish dysplastic and neoplastic le-
sions from healthy tissue.
Over the past decade, numerous biomarkers have been re-
ported to play an important role in colorectal cancer. Examples154 Chemistry & Biology 22, 148–158, January 22, 2015 ª2015 Elsevof promising biomarkers for colorectal cancer with suitable
characteristics such as high expression rates, specificity, and
high signal-to-background ratio include CXCR4, MMPs,
EGFR, VEGF-A, Muc-1, and EpCAM (van Oosten et al.,
2011). Recent studies described an essential role of cysteine
cathepsins in colorectal cancer and a strong correlation be-
tween cathepsin activity and clinical and pathological features
(Kuester et al., 2008). More specifically, cathepsins B, D, L, S,
and X are generally upregulated in colorectal carcinomas both
in epithelial cells and in tumor-supporting cells such as macro-
phages, fibroblasts, and endothelial cells (Hersze´nyi et al.,ier Ltd All rights reserved
Figure 6. The qABP Probe Labels Cathepsins in Human Polyps with Similar Labeling Specificity Observed in Mouse Models
Bright-field and confocal macroscopic mosaic images of matched normal colon tissue and tumor tissue. The top row shows matched normal colon stained with
H&E (left; the scale bar represents 1 mm) and DAPI (blue) or qABP (red) or overlay on right. The middle row shows matched tumor with H&E (left; the scale bar
represents 1 mm) and DAPI (blue) or qABP (red) or overlay on right. (Bottom row, left) A 203 image (left; the scale bar represents 100 mm) of the qABP and 633
images (right; the scale bar represents 20 mm) of qABP (red), CD45 (green), or overlay with DAPI (blue) staining of the region designated by the white box on the
left.
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with these studies, we show strong labeling of cathepsins X,
B, S, and L in samples of adenomas from APCmin/+ and
AOM/DSS mice treated with the qABP. Cathepsin S has
been suggested as a relevant biomarker in colorectal cancer
and is expressed in 95% of cases of primary human colorectal
tumors (Gormley et al., 2011). Furthermore, cathepsin S has
significantly higher expression rates in colorectal tumors
compared with matched healthy surrounding colonic mucosa.
Here, we report that in samples from AOM/DSS mice intrave-
nously treated with the probe, we observed strong labeling of
cathepsin S both in adenomas and in matched normal intesti-
nal mucosa, whereas in AOM/DSS mice locally treated with
the probe, we observed strong labeling of cathepsin S in ade-
nomas but not in surrounding intestinal mucosa. Because
cathepsin S is mostly expressed by macrophages, it is
possible that when administered intravenously, the probe is
more accessible to macrophages than when administered
locally, because of only partial penetration through the colonic
mucosal layer. This might also explain the improved sensitivity
and specificity that we achieved in the AOM/DSS model whenChemistry & Biology 22, 148the probe was administered locally to the colon by intrarectal
injection.
Several optical molecular probes with different functional
characteristics for detection of colorectal adenomas have been
described previously (Sheth and Mahmood, 2010). These
include nonspecific, targeted, and activatable probes, such as
MMPSense 680, which is a near-infrared substrate-based probe
that is activated by a broad array of MMP enzymes to detect
early colorectal adenomas (Clapper et al., 2011). Optimal
signal-to-noise ratio was achieved 66 hr after administration of
the probe to APCmin/+ mice, and sensitivity and specificity
were 67% and 97%. Other examples include a targeted hepta-
peptide for colonic dysplasia that was isolated using a phage
library screening approach (Hsiung et al., 2008), a near-infrared
octapeptide for dysplastic lesions (Miller et al., 2011), and
ProSense 680 that was used to target cysteine cathepsins upre-
gulated in colon polyps (Gounaris et al., 2008). Even though
these probes accumulate at colorectal lesions, the long pretreat-
ment times needed to achieve optimal signal-to-background
ratio, combined with the relatively low sensitivity and specificity,
hamper their use in the clinical setting.–158, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 155
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Colon cancer remains one of the most treatable forms of
cancer if detected early. Currently, screening by endoscopic
methods can virtually eliminate the mortality associated
with this disease, yet it is currently not possible to achieve
comprehensive screening of all adults over the age of
50 years. Therefore, simplemethods to detect early stage le-
sionswill eventually enable rapid and simple identification of
those at risk for having this disease so that more advanced
interventional methods can be initiated. Here, we describe
a highly selective Cy5-labeled qABP that binds covalently
to the catalytic active site of cysteine cathepsin proteases.
These proteases are highly expressed in immune inflamma-
tory cells that infiltrate into a nascent tumor tissue, thus
making them ideal imaging biomarkers. In contrast to the
substrate-based probes that have been used to image
protease activities in various forms of cancer, the qABP pre-
sented here generates fluorescence rapidly (<1 hr) and
labels intestinal polyps in both mouse models of colon can-
cer and in human polyp tissues with high sensitivity and
selectivity. Furthermore, the probe is effective when admin-
istered directly to the colon, thereby reducing accumulation
in other organs. These unique functional characteristics
make this qABP a clinically promising tool that could be
used for the detection of colonic polyps either directly in
combination with conventional colonoscopy or for prescre-
ening that could allow identification of at-risk patients in
need of interventional procedures. The studies presented
here serve as proof-of-concept studies that should enable
advancement of the current optical probe into clinical trials
for these applications.
EXPERIMENTAL PROCEDURES
General
Unless otherwise noted, all reagents were purchased from commercial sup-
pliers and used without further purifications. All solvents used were high-per-
formance liquid chromatography grade. Fluorescent gels were scanned using
a Typhoon 9400 flatbed laser scanner (GE Healthcare).
Animal Models
For the genetic mouse model of intestinal cancer, we used the C57BL/6J-
ApcMin/J (APCmin/+) strain that is susceptible to spontaneous intestinal
adenoma formation (Jackson Laboratory). Male APCmin/+ mice aged 8 to
10 weeks were injected intravenously with 10 nmol of the probe. One
hour later, mice were euthanized, and intestines were dissected, flushed
with PBS, and processed for further analysis. An inflammation-related
mouse colon carcinogenesis model was established as previously
described (Neufert et al., 2007). Briefly, 6- to 8-week-old mice were injected
intraperitoneally with AOM (Sigma-Aldrich) at a concentration of 10 mg/kg.
On day 5 after AOM injection, mice were treated with 2% DSS (molecular
weight 36,000–50,000 Da; MP Biomedicals) in drinking water for 5 consec-
utive days, which was followed by 16 days of regular drinking water admin-
istration. This DSS treatment was repeated for two additional cycles. During
the course of the experiment, mice were monitored for body weight, diar-
rhea, and macroscopic bleeding. On day 35 of the regime, mice were in-
jected intravenously or intrarectally with 10 nmol of the probe. One hour
later, mice were euthanized, and colons were dissected, flushed with
PBS, and processed for further analysis. For inhibitor studies, 100 mg/kg
of K11777 or vehicle was injected intraperitoneally twice daily in 40%
DMSO/sterile PBS in a total volume of 100 ml each day for 5 days before
probe administration.156 Chemistry & Biology 22, 148–158, January 22, 2015 ª2015 ElsevEx Vivo Imaging of Colons and Intestines
Mice were euthanized, and intestines or colons were removed, flushed with
PBS, and opened longitudinally. Colons or intestines were imaged using the
IVIS 100 system with a Cy5.5 filter (Xenogen). Images were evaluated using
Living Image software (PerkinElmer). Macroscopic polyp diameters were
measured by caliper, and signal intensity per millimeter per millisecond (expo-
sure time) of labeled polyps was calculated using IVIS software.
SDS-PAGE Gel Analysis
Samples were collected and sonicated (1 min on ice) in citrate buffer (50 mM
citrate buffer [pH 5.5], 5 mM dithiothreitol, 0.5% 3-[3-cholamidopropyl]-dime-
thylammoniopropane sulfonate [CHAPS], 0.1% Triton X). After centrifugation
at 4C for 30 min, the supernatants were collected, and protein concentration
was determined using a BCA kit (Pierce). Protein (40 mg total) was denatured in
SDS-sample buffer for 2 min at 100C and analyzed. Samples were resolved
by SDS-PAGE (15%), and labeled proteases were visualized by scanning
the gel with a Typhoon fluorescence imager (GE Healthcare).
Gel Staining with Coomassie Blue
SDS-PAGE gels were stained with 0.1% Coomassie blue staining (Life Tech-
nologies) in 10% acetic acid, 50% methanol, and 40% H2O for the minimum
time (typically 1 hr) necessary to visualize the bands with shaking and at least
three solvent changes to ensure adequate removal of SDS. Gels were then de-
stained by soaking for at least 2 hr in 10%acetic acid, 50%methanol, and 40%
H2O with at least two changes of this solvent.
Immunohistochemistry
Immunohistochemistry of intestine samples and polyps was performed using
5-mm-thick, formalin-fixed, paraffin-embedded tissue sections. Paraffin sec-
tions were deparaffinized, rehydrated, and stained by H&E. For immunofluo-
rescence, intestines were flushed with 2% paraformaldehyde and then fixed
for 2 hr in 2% paraformaldehyde at 4C. Tissues were then transferred to
30% sucrose solution and incubated overnight at 4C for cryopreservation.
Tissues were washed with 50% optimal cutting temperature (OCT) medium
in PBS prior to embedding in OCT and freezing. Six-micrometer-thick sections
were cut and fixed in acetone, blocked with 5% goat serum in 1% BSA/PBS,
followed by incubation with fluorescein isothiocyanate (FITC) rat antimouse
CD45 antibody (1:200; Biolegend) for 1 hr at room temperature. AlexaFluor488
goat-anti FITC (1:1000; Invitrogen) was incubated for 30 min at room temper-
ature in order to improve FITC signal. Sections were then stained with DAPI
(2mg/mL; Invitrogen) for 5 min and then mounted in ProLong Gold Mounting
Medium (Invitrogen).
Freshly isolated human tissues were frozen in OCT prior to sectioning. Six-
micrometer-thick sections were fixed for 10min in acetone at20C, and sec-
tions were blocked in 1% BSA with 5% goat serum and then stained for 1 hr
with 1 mM BMV109 in citrate buffer (50 mM citrate buffer [pH 5.5], 5 mM
DDT, 0.5% CHAPS, 0.1% Triton X) and 1:25 diluted FITC mouse antihuman
CD45 antibody (Becton Dickinson) at room temperature. Slides were washed,
and FITC signal was amplified using 1:2000 diluted Alexa Fluor 488-conju-
gated goat anti-FITC antibody (Life Technologies) for 20 min at room
temperature.
Confocal Microscopy
Localization of the probe in mouse intestines was imaged using a Zeiss LSM
700 confocal imaging systems equipped with 633 oil objective and motorized
stage. All images were taken using a multitrack channel acquisition to prevent
emission crosstalk between fluorescent dyes. Single XY, XZ plane images
were acquired in 1,024 3 1,024 resolution. Images were processed as sepa-
rate channels using Huygens deconvolution software or ImageJ and merged
as a single image.Mosaic images of H&E and fluorescence labeling were taken
using 203 objective and stitched using 15% overlay.
Sensitivity and Specificity Analysis
Bright-field and fluorescence ex vivo images of colons and intestines were ac-
quired as described above. The number and size of polyps and matched fluo-
rescence intensity were analyzed using ImageJ analysis software. First, the
threshold was set for each grayscale binary image. True scale was set on
the basis of the scale bar of the images acquired by IVIS 100 system. Theier Ltd All rights reserved
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‘‘Show Masks’’ was selected to display a drawing of the detected objects.
Fluorescence intensity for each individual polyp was calculated by the analysis
of the gray levels across the entire colons or intestines. Information on signal
intensity, polyp number, and diameter was used for sensitivity and specificity
analysis. Calculations were based on the following definitions: (1) true posi-
tives are polyps correctly labeled, (2) false positives are healthy tissue incor-
rectly labeled, (3) true negatives are healthy tissue not labeled, and (4) false
negatives are polyps incorrectly not labeled. We used common equations
for calculation of sensitivity, a/(a + c); specificity, d/(b + d); positive likelihood
ratio, [a/(a + c)]/[b/(b + d)]; negative likelihood ratio, [c/(a + c)]/[d/(b + d)]; pos-
itive predictive value, a/(a + b); and negative predictive value, d/(c + d).
Statistical Analysis
Statistical analysis was performed using Microsoft Excel, and SEMwas calcu-
lated by dividing the SD by the square root of n. Statistical significance was
determined using an unpaired t test; p values < 0.05 were considered statisti-
cally significant. All statistical tests were two sided.
Animal Protocol Approval
All animal care and experimentation was conducted in accord with current NIH
and Stanford University Institutional Animal Care and Use Committee guide-
lines under protocol APLAC-18026.
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